Retinal ganglion cell neurodegeneration in mitochondrial inherited disorders

Biochimica et Biophysica Acta - Bioenergetics

Volumn 1787, Issue 5, 2009, Pages 518-528

  Carelli, Valerio ^a   La Morgia, Chiara ^a   Valentino, Maria Lucia ^a   Barboni, Piero ^a   Ross Cisneros, Fred N ^b   Sadun, Alfredo A ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Complex I; DOA; LHON; Mitochondrial DNA; Neurodegeneration; OPA1; Optic nerve; Optic neuropathy; Retinal ganglion cell

Indexed keywords

GLUTAMIC ACID; MITOCHONDRIAL DNA; MITOCHONDRIAL PROTEIN;

APOPTOSIS; BIOENERGY; CMT2A GENE; COSTEFF SYNDROME; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FRIEDREICH ATAXIA; FXN GENE; GENE; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; HUMAN CELL; LEBER HEREDITARY OPTIC ATROPHY KJER TYPE; LEBER HEREDITARY OPTIC NEUROPATHY; MELAS SYNDROME; MFN2 GENE; MOHR TRANEBJERG SYNDROME; NERVE DEGENERATION; NERVE FIBER TRANSPORT; OPA1 GENE; OPA3 GENE; OPTIC NERVE ATROPHY; OXIDATIVE STRESS; PATHOGENESIS; POINT MUTATION; PRIORITY JOURNAL; RETINA GANGLION CELL; REVIEW; SPG7 GENE; TIMM8A GENE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CELL CYCLE PROTEINS; CELL NUCLEUS; DNA; DNA, MITOCHONDRIAL; FRIEDREICH ATAXIA; GTP PHOSPHOHYDROLASES; HUMANS; MEMBRANE PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; MITOCHONDRIAL DISEASES; MITOCHONDRIAL PROTEINS; NERVE DEGENERATION; NUCLEAR PROTEINS; OPTIC ATROPHY, HEREDITARY, LEBER; OROFACIODIGITAL SYNDROMES; RETINAL GANGLION CELLS;

EID: 65449154775     PISSN: 00052728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbabio.2009.02.024     Document Type: Review

References (143)

1. Sadun A.A., and Glaser J.S. Chapter 4, anatomy of the visual sensory system. In: Glaser J.S. (Ed). Neuro-ophthalmology. 3rd Ed (1999), Lippincott Williams and Wilkins, Philadelphia 75-94
2. Carelli V., Ross-Cisneros F.N., and Sadun A.A. Mitochondrial dysfunction as a cause of optic neuropathies. Prog. Retin. Eye Res. 23 (2004) 53-89
3. Carelli V., La Morgia C., Iommarini L., Carroccia R., Mattiazzi M., Sangiorgi S., Farne' S., Maresca A., Foscarini B., Lanzi L., Amadori M., Bellan M., and Valentino M.L. Mitochondrial optic neuropathies: how two genomes may kill the same cell type?. Biosci. Rep. 27 (2007) 173-184
4. Yu-Wai-Man P., Chinnery P.F., and Griffiths P.G. Optic neuropathies-importance of spatial distribution of mitochondria as well as function. Med. Hypotheses 65 (2005) 1038-1042
5. Carelli V., Barboni P., and Sadun A.A. Chapter 5. Mitochondrial ophthalmology. In: Di Mauro S., Hirano M., and Schon E. (Eds). Mitochondrial medicine (2006), Informa Healthcare Abingdon, Oxon, UK 105-142
6. Leber T. Uber hereditare und congenital-angelegte Sehnervenleiden. Arch. Ophthalmol. 17 (1871) 249-291
7. Wallace D.C., Singh G., Lott M.T., Hodge J.A., Schurr T.G., Lezza A.M., Elsas L.J., and Nikoskelainen E.K. Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science 242 (1988) 1427-1430
8. Kjer P. Infantile optic atrophy with dominant mode of inheritance: a clinical and genetic study of 19 Danish families. Acta Ophthalmol. Scand. 37 (1959) 1-146
9. Alexander C., Votruba M., Pesch U.E.A., Thiselton D.L., Mayer S., Moore A., Rodriguez M., Kellner U., Leo-Kottler B., Auburger G., Bhattacharya S.S., and Wissinger B. OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28. Nat. Genet. 26 (2000) 211-215
10. Delettre C., Lenaers G., Griffoin J.-M., Gigarel N., Lorenzo C., Belenguer P., Pelloquin L., Grosgeorge J., Turc-Carel C., Perret E., Astarie-Dequeker C., Lasquellec L., Arnaud B., Ducommun B., Kaplan J., and Hamel C.P. Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy. Nat. Genet. 26 (2000) 207-210
11. Yu-Wai-Man P., Griffiths P.G., Hudson G., and Chinnery P.F. Inherited mitochondrial optic neuropathies. J. Med. Genet. 46 3 (2009) 145-158
12. Ruiter E.M., Siers M.H., van den Elzen C., van Engelen B.G., Smeitink J.A., Rodenburg R.J., and Hol F.A. The mitochondrial 13513G>A mutation is most frequent in Leigh syndrome combined with reduced complex I activity, optic atrophy and/or Wolff-Parkinson-White. Eur. J. Hum. Genet. 15 (2007) 155-161
13. Pulkes T., Eunson L., Patterson V., Siddiqui A., Wood N.W., Nelson I.P., Morgan-Hughes J.A., and Hanna M.G. The mitochondrial DNA G13513A transition in ND5 is associated with a LHON/MELAS overlap syndrome and may be a frequent cause of MELAS. Ann. Neurol. 46 (1999) 916-919
14. Spruijt L., Smeets H.J., Hendrickx A., Bettink-Remeijer M.W., Maat-Kievit A., Schoonderwoerd K.C., Sluiter W., de Coo I.F., and Hintzen R.Q. A MELAS-associated ND1 mutation causing Leber hereditary optic neuropathy and spastic dystonia. Arch. Neurol. 64 (2007) 890-893
15. Blakely E.L., de Silva R., King A., Schwarzer V., Harrower T., Dawidek G., Turnbull D.M., and Taylor R.W. LHON/MELAS overlap syndrome associated with a mitochondrial MTND1 gene mutation. Eur. J. Hum. Genet. 13 (2005) 623-627
16. Valentino M.L., Barboni P., Rengo C., Achilli A., Torroni A., Lodi R., Tonon C., Barbiroli B., Fortuna F., Montagna P., Baruzzi A., and Carelli V. The 13042G → A/ND5 mutation in mtDNA is pathogenic and can be associated also with a prevalent ocular phenotype. J. Med. Genet. 43 (2006) e38
17. Fortuna F., Barboni P., Liguori R., Valentino M.L., Savini G., Gellera C., Mariotti C., Rizzo G., Tonon C., Manners D., Lodi R., Sadun A.A., and Carelli V. Visual system involvement in patients with Friedreich's ataxia. Brain 132 (2009) 116-123
18. Tranebjaerg L., Jensen P.K., Van Ghelue M., Vnencak-Jones C.L., Sund S., Elgjo K., Jakobsen J., Lindal S., Warburg M., Fuglsang-Frederiksen A., and Skullerud K. Neuronal cell death in the visual cortex is a prominent feature of the X-linked recessive mitochondrial deafness-dystonia syndrome caused by mutations in the TIMM8a gene. Ophthalmic Genet. 22 (2001) 207-223
19. Casari G., De Fusco M., Ciarmatori S., Zeviani M., Mora M., Fernandez P., De Michele G., Filla A., Cocozza S., Marconi R., Dürr A., Fontaine B., and Ballabio A. Spastic paraplegia and OXPHOS impairment caused by mutations in paraplegin, a nuclear-encoded mitochondrial metalloprotease. Cell 93 (1998) 973-983
20. Amati-Bonneau P., Valentino M.L., Reynier P., Gallardo M.E., Bornstein B., Boissière A., Campos Y., Rivera H., de la Aleja J.G., Carroccia R., Iommarini L., Labauge P., Figarella-Branger D., Marcorelles P., Furby A., Beauvais K., Letournel F., Liguori R., La Morgia C., Montagna P., Liguori M., Zanna C., Rugolo M., Cossarizza A., Wissinger B., Verny C., Schwarzenbacher R., Martín M.A., Arenas J., Ayuso C., Garesse R., Lenaers G., Bonneau D., and Carelli V. OPA1 mutations induce mitochondrial DNA instability and optic atrophy 'plus' phenotypes. Brain 131 (2008) 338-351
21. Hudson G., Amati-Bonneau P., Blakely E.L., Stewart J.D., He L., Schaefer A.M., Griffiths P.G., Ahlqvist K., Suomalainen A., Reynier P., McFarland R., Turnbull D.M., Chinnery P.F., and Taylor R.W. Mutation of OPA1 causes dominant optic atrophy with external ophthalmoplegia, ataxia, deafness and multiple mitochondrial DNA deletions: a novel disorder of mtDNA maintenance. Brain 131 (2008) 329-337
22. Voo I., Allf B.E., Udar N., Silva-Garcia R., Vance J., and Small K.W. Hereditary motor and sensory neuropathy type VI with optic atrophy. Am. J. Ophthalmol. 136 (2003) 670-677
23. Züchner S., Mersiyanova I.V., Muglia M., Bissar-Tadmouri N., Rochelle J., Dadali E.L., Zappia M., Nelis E., Patitucci A., Senderek J., Parman Y., Evgrafov O., Jonghe P.D., Takahashi Y., Tsuji S., Pericak-Vance M.A., Quattrone A., Battaloglu E., Polyakov A.V., Timmerman V., Schröder J.M., and Vance J.M. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat. Genet. 36 (2004) 449-451
24. Züchner S., De Jonghe P., Jordanova A., Claeys K.G., Guergueltcheva V., Cherninkova S., Hamilton S.R., Van Stavern G., Krajewski K.M., Stajich J., Tournev I., Verhoeven K., Langerhorst C.T., de Visser M., Baas F., Bird T., Timmerman V., Shy M., and Vance J.M. Axonal neuropathy with optic atrophy is caused by mutations in mitofusin 2. Ann. Neurol. 59 (2006) 276-281
25. Costeff H., Gadoth N., Apter N., Prialnic M., and Savir H. A familial syndrome of infantile optic atrophy, movement disorder, and spastic paraplegia. Neurology 39 (1989) 595-597
26. Anikster Y., Kleta R., Shaag A., Gahl W.A., and Elpeleg O. Type III 3-methylglutaconic aciduria (optic atrophy plus syndrome, or Costeff optic atrophy syndrome): identification of the OPA3 gene and its founder mutation in Iraqi Jews. Am. J. Hum. Genet. 69 (2001) 1218-1224
27. Reynier P., Amati-Bonneau P., Verny C., Olichon A., Simard G., Guichet A., Bonnemains C., Malecaze F., Malinge M.C., Pelletier J.B., Calvas P., Dollfus H., Belenguer P., Malthièry Y., Lenaers G., and Bonneau D. OPA3 gene mutations responsible for autosomal dominant optic atrophy and cataract. J. Med. Genet. 41 (2004) e110
28. Verny C., Amati-Bonneau P., Dubas F., Malthiéry Y., Reynier P., and Bonneau D. An OPA3 gene mutation is responsible for the disease associating optic atrophy and cataract with extrapyramidal signs. Rev. Neurol. (Paris) 161 (2005) 451-454
29. Howell N., Bindoff L.A., McCullough D.A., Kubacka I., Poulton J., Mackey D., Taylor L., and Turnbull D.M. Leber hereditary optic neuropathy: identification of the same mitochondrial ND1 mutation in six pedigrees. Am. J. Hum. Genet. 49 (1991) 939-950
30. Johns D.R., Neufeld M.J., and Park R.D. An ND-6 mitochondrial DNA mutation associated with Leber hereditary optic neuropathy. Biochem. Biophys. Res. Comm. 187 (1992) 1551-1557
31. Man P.Y., Griffiths P.G., Brown D.T., Howell N., Turnbull D.M., and Chinnery P.F. The epidemiology of Leber hereditary optic neuropathy in the North East of England. Am. J. Hum. Genet. 72 (2003) 333-339
32. Smith J.L., Hoyt W.F., and Susac J.O. Ocular fundus in acute Leber optic neuropathy. Arch. Ophthalmol. 90 (1973) 349-354
33. Nikoskelainen E., Hoyt W.F., and Nummelin K. Ophthalmoscopic findings in Leber's hereditary optic neuropathy. II. The fundus findings in affected family members. Arch. Ophthalmol. 101 (1983) 1059-1068
34. Nikoskelainen E., Hoyt W.F., Nummelin K., and Schatz H. Fundus findings in Leber's hereditary optic neuropathy. III. Fluorescein angiographic studies. Arch. Ophthalmol. 102 (1984) 981-989
35. Nikoskelainen E., Hoyt W.F., and Nummelin K. Ophthalmoscopic findings in Leber's hereditary optic neuropathy. I. Fundus findings in asymptomatic family members. Arch. Ophthalmol. 100 (1982) 1597-1602
36. Lüdtke H., Kriegbaum C., Leo-Kottler B., and Wilhelm H. Pupillary light reflexes in patients with Leber's hereditary optic neuropathy. Graefes Arch. Clin. Exp. Ophthalmol. 237 (1999) 207-211
37. Bose S., Dhillon N., Ross-Cisneros F.N., and Carelli V. Relative post-mortem sparing of afferent pupil fibers in a patient with 3460 Leber's hereditary optic neuropathy. Graefes Arch. Clin. Exp. Ophthalmol. 243 (2005) 1175-1179
38. Stone E.M., Newman N.J., Miller N.R., Johns D.R., Lott M.T., and Wallace D.C. Visual recovery in patients with Leber's hereditary optic neuropathy and the 11778 mutation. J. Clin. Neuroophthalmol. 12 (1992) 10-14
39. Mackey D., and Howell N. A variant of Leber hereditary optic neuropathy characterized by recovery of vision and by an unusual mitochondrial genetic etiology. Am. J. Hum. Genet. 51 (1992) 1218-1228
40. Pezzi P.P., De Negri A.M., Sadun F., Carelli V., and Leuzzi V. Childhood Leber's hereditary optic neuropathy (ND1/3460) with visual recovery. Pediatr. Neurol. 19 (1998) 308-312
41. Sadun A.A., Kashima Y., Wurdeman A.E., Dao J., Heller K., and Sherman J. Morphological findings in the visual system in a case of Leber's hereditary optic neuropathy. Clin. Neurosci. 2 (1994) 165-172
42. Sadun A.A., Win P.H., Ross-Cisneros F.N., Walker S.O., and Carelli V. Leber's hereditary optic neuropathy differentially affects smaller axons in the optic nerve. Trans. Am. Ophthalmol. Soc. 98 (2000) 223-232
43. Barboni P., Savini G., Valentino M.L., Montagna P., Cortelli P., De Negri A.M., Sadun F., Bianchi S., Longanesi L., Zanini M., De Vivo A., and Carelli V. Retinal nerve fiber layer evaluation by optical coherence tomography in Leber's hereditary optic neuropathy. Ophthalmology 112 (2005) 120-126
44. Savini G., Zanini M., Carelli V., Sadun A.A., Ross-Cisneros F.N., and Barboni P. Correlation between retinal nerve fibre layer thickness and optic nerve head size: an optical coherence tomography study. Br. J. Ophthalmol. 89 (2005) 489-492
45. Carelli V., Achilli A., Valentino M.L., Rengo C., Semino O., Pala M., Olivieri A., Mattiazzi M., Pallotti F., Carrara F., Zeviani M., Leuzzi V., Carducci C., Valle G., Simionati B., Mendieta L., Salomao S., Belfort Jr. R., Sadun A.A., and Torroni A. Haplogroup effects and recombination of mitochondrial DNA: novel clues from the analysis of Leber hereditary optic neuropathy pedigrees. Am. J. Hum. Genet. 78 (2006) 564-574
46. Hudson G., Carelli V., Spruijt L., Gerards M., Mowbray C., Achilli A., Pyle A., Elson J., Howell N., La Morgia C., Valentino M.L., Huoponen K., Savontaus M.L., Nikoskelainen E., Sadun A.A., Salomao S.R., Belfort Jr. R., Griffiths P., Man P.Y., de Coo R.F., Horvath R., Zeviani M., Smeets H.J., Torroni A., and Chinnery P.F. Clinical expression of Leber hereditary optic neuropathy is affected by the mitochondrial DNA-haplogroup background. Am. J. Hum. Genet. 81 (2007) 228-233
47. La Morgia C., Achilli A., Iommarini L., Barboni P., Pala M., Olivieri A., Zanna C., Vidoni S., Tonon C., Lodi R., Vetrugno R., Mostacci B., Liguori R., Carroccia R., Montagna P., Rugolo M., Torroni A., and Carelli V. Rare mtDNA variants in Leber hereditary optic neuropathy families with recurrence of myoclonus. Neurology 70 (2008) 762-770
48. Carelli V., Giordano C., and d'Amati G. Pathogenic expression of homoplasmic mtDNA mutations needs a complex nuclear-mitochondrial interaction. Trends Genet. 19 (2003) 257-262
49. Bu X.D., and Rotter J.I. X chromosome-linked and mitochondrial gene control of Leber hereditary optic neuropathy: evidence from segregation analysis for dependence on X chromosome inactivation. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 8198-8202
50. Hudson G., Keers S., Yu W.M.P., Griffiths P., Huoponen K., Savontaus M.L., Nikoskelainen E., Zeviani M., Carrara F., Horvath R., Karcagi V., Spruijt L., de Coo I.F., Smeets H.J., and Chinnery P.F. Identification of an X-chromosomal locus and haplotype modulating the phenotype of a mitochondrial DNA disorder. Am. J. Hum. Genet. 77 (2005) 1086-1091
51. Shankar S.P., Fingert J.H., Carelli V., Valentino M.L., King T.M., Daiger S.P., Salomao S.R., Berezovsky A., Belfort Jr. R., Braun T.A., Sheffield V.C., Sadun A.A., and Stone E.M. Evidence for a novel x-linked modifier locus for leber hereditary optic neuropathy. Ophthalmic Genet. 29 (2008) 17-24
52. Hudson G., Carelli V., Horvath R., Zeviani M., Smeets H.J., and Chinnery P.F. X-Inactivation patterns in females harboring mtDNA mutations that cause Leber hereditary optic neuropathy. Mol. Vis. 13 (2007) 2339-2343
53. Sadun A.A., Carelli V., Salomao S.R., Berezovsky A., Quiros P.A., Sadun F., DeNegri A.M., Andrade R., Moraes M., Passos A., Kjaer P., Pereira J., Valentino M.L., Schein S., and Belfort R. Extensive investigation of a large Brazilian pedigree of 11778/haplogroup J Leber hereditary optic neuropathy. Am. J. Ophthalmol. 136 (2003) 231-238
54. Carelli V., Franceschini F., Venturi S., Barboni P., Savini G., Barbieri G., Pirro E., La Morgia C., Valentino M.L., Zanardi F., Violante F.S., and Mattioli S. Grand rounds: could occupational exposure to n-hexane and other solvents precipitate visual failure in leber hereditary optic neuropathy?. Environ. Health Perspect. 115 (2007) 113-115
55. Ghelli A., Zanna C., Porcelli A.M., Schapira A.H., Martinuzzi A., Carelli V., and Rugolo M. Leber's hereditary optic neuropathy (LHON) pathogenic mutations induce mitochondrial-dependent apoptotic death in transmitochondrial cells incubated with galactose medium. J. Biol. Chem. 278 (2003) 4145-4150
56. Zanna C., Ghelli A., Porcelli A.M., Martinuzzi A., Carelli V., and Rugolo M. Caspase-independent death of Leber's hereditary optic neuropathy cybrids is driven by energetic failure and mediated by AIF and endonuclease G. Apoptosis 10 (2005) 997-1007
57. Newman N.J., Biousse V., David R., Bhatti M.T., Hamilton S.R., Farris B.K., Lesser R.L., Newman S.A., Turbin R.E., Chen K., and Keaney R.P. Prophylaxis for second eye involvement in Leber hereditary optic neuropathy: an open-labeled, nonrandomized multicenter trial of topical brimonidine purite. Am. J. Ophthalmol. 140 (2005) 407-415
58. Delettre C., Lenaers G., Pelloquin L., Belenguer P., and Hamel C.P. OPA1 (Kjer type) dominant optic atrophy: a novel mitochondrial disease. Mol. Genet. Metab. 75 (2002) 97-107
59. Cohn A.C., Toomes C., Hewitt A.W., Kearns L.S., Inglehearn C.F., Craig J.E., and Mackey D.A. The natural history of OPA1-related autosomal dominant optic atrophy. Br. J. Ophthalmol. 92 (2008) 1333-1336
60. Votruba M., Thiselton D., and Bhattacharya S.S. Optic disc morphology of patients with OPA1 autosomal dominant optic atrophy. Br. J. Ophthalmol. 87 (2003) 48-53
61. Cohn A.C., Toomes C., Potter C., Towns K.V., Hewitt A.W., Inglehearn C.F., Craig J.E., and Mackey D.A. Autosomal dominant optic atrophy: penetrance and expressivity in patients with OPA1 mutations. Am. J. Ophthalmol. 143 (2007) 656-662
62. Kjer P., Jensen O.A., and Klinken L. Histopathology of eye, optic nerve and brain in a case of dominant optic atrophy. Acta Ophthalmol. (Copenh) 61 (1983) 300-312
63. Johnston P.B., Gaster R.N., Smith V.C., and Tripathi R.C. A clinicopathologic study of autosomal dominant optic atrophy. Am. J. Ophthalmol. 88 (1979) 868-875
64. Kerrison J.B., Arnould V.J., Ferraz Sallum J.M., Vagefi M.R., Barmada M.M., Li Y., Zhu D., and Maumenee I.H. Genetic heterogeneity of dominant optic atrophy, Kjer type: identification of a second locus on chromosome 18q12.2-12.3. Arch. Ophthalmol. 117 (1999) 805-810
65. Barbet F., Hakiki S., Orssaud C., Gerber S., Perrault I., Hanein S., Ducroq D., Dufier J.L., Munnich A., Kaplan J., and Rozet J.M. A third locus for dominant optic atrophy on chromosome 22q. J. Med. Genet. 42 (2005) e1
66. Ferre M., Amati-Bonneau P., Tourmen Y., Malthiery Y., and Reynier P. eOPA1: an online database for OPA1 mutations. Hum. Mutat. 25 (2005) 423-428
67. Praefcke G.J.K., and McMahon H.T. The dynamin superfamily: universal membrane tubulation and fission molecules?. Nat. Rev. 5 (2004) 133-147
68. Hoppins S., Lackner L., and Nunnari J. The machine that divide and fuse mitochondria. Ann. Rev. Biochem. 76 (2007) 751-780
69. Olichon A., Guillou E., Delettre C., Landes T., Arnauné-Pelloquin L., Emorine L.J., Mils V., Daloyau M., Hamel C., Amati-Bonneau P., Bonneau D., Reynier P., Lenaers G., and Belenguer P. Mitochondrial dynamics and disease, OPA1. Biochim. Biophys. Acta 1763 (2006) 500-509
70. Olichon A., Baricault L., Gas N., Guillou E., Valette A., Belenguer P., and Lenaers G. Loss of OPA1 perturbates the mitochondrial inner membrane structure and integrity, leading to cytochrome c release and apoptosis. J. Biol. Chem. 278 (2003) 7743-7746
71. Frezza C., Cipolat S., Martins de Brito O., Micaroni M., Beznoussenko G.V., Rudka T., Bartoli D., Polishuck R.S., Danial N.N., De Strooper B., and Scorrano L. OPA1 controls apoptotic cristae remodeling independently from mitochondrial fusion. Cell 126 (2006) 177-189
72. Lodi R., Tonon C., Valentino M.L., Iotti S., Clementi V., Malucelli E., Barboni P., Longanesi L., Schimpf S., Wissinger B., Baruzzi A., Barbiroli B., and Carelli V. Deficit of in vivo mitochondrial ATP production in OPA1-related dominant optic atrophy. Ann. Neurol. 56 (2004) 719-723
73. Zanna C., Ghelli A., Porcelli A.M., Karbowski M., Youle R.J., Schimpf S., Wissinger B., Pinti M., Cossarizza A., Vidoni S., Valentino M.L., Rugolo M., and Carelli V. OPA1 mutations associated with dominant optic atrophy impair oxidative phosphorylation and mitochondrial fusion. Brain 131 (2008) 352-367
74. Chevrollier A., Guillet V., Loiseau D., Gueguen N., de Crescenzo M.A., Verny C., Ferre M., Dollfus H., Odent S., Milea D., Goizet C., Amati-Bonneau P., Procaccio V., Bonneau D., and Reynier P. Hereditary optic neuropathies share a common mitochondrial coupling defect. Ann. Neurol. 63 (2008) 794-798
75. Chinnery P.F., Howell N., Lightowlers R.N., and Turnbull D.M. Molecular pathology of MELAS and MERRF. The relationship between mutation load and clinical phenotypes. Brain 120 (1997) 1713-1721
76. [Leu(UUR)] A3243G mutation. Ophthalmic Genet. 18 (1997) 101-105
77. Cavanagh J.B., and Harding B.N. Pathogenic factors underlying the lesions in Leigh's disease. Tissue responses to cellular energy deprivation and their clinico-pathological consequences. Brain 117 (1994) 1357-1376
78. DiMauro S., and Schon E.A. Mitochondrial disorders in the nervous system. Annu. Rev. Neurosci. 31 (2008) 91-123
79. Jun A.S., Brown M.D., and Wallace D.C. A mitochondrial DNA mutation at nucleotide pair 14459 of the NADH dehydrogenase subunit 6 gene associated with maternally inherited Leber hereditary optic neuropathy and dystonia. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 6206-6210
80. Kirby D.M., Kahler S.G., Freckmann M.-L., Reddihough D., and Thorburn D.R. Leigh disease caused by the mitochondrial DNA G14459A mutation in unrelated families. Ann. Neurol. 48 (2000) 102-104
81. Santorelli F.M., Tanji K., Kulikova R., Shanske S., Vilarinho L., Hays A.P., and DiMauro S. Identification of a novel mutation in the mtDNA ND5 gene associated with MELAS. Biochem. Biophys. Res. Commun. 238 (1997) 326-328
82. Corona P., Antozzi C., Carrara F., D'Incerti L., Lamantea E., Tiranti V., and Zeviani M. A novel mtDNA mutation in the ND5 subunit of complex I in two MELAS patients. Ann. Neurol. 49 (2001) 106-110
83. Funalot B., Reynier P., Vighetto A., Ranoux D., Bonnefont J.P., Godinot C., Malthiery Y., and Mas J.L. Leigh-like encephalopathy complicating Leber's hereditary optic neuropathy. Ann. Neurol. 52 (2002) 374-377
84. Nikoskelainen E.K. Clinical picture of LHON. Clin. Neurosci. 2 (1994) 115-120
85. Sakuta R., and Nonaka I. Vascular involvement in mitochondrial myopathy. Ann. Neurol. 25 (1989) 594-601
86. Hasegawa H., Matsuoka T., Goto Y., and Nonaka I. Strongly succinate dehydrogenase reactive blood vessels in muscles from patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes. Ann. Neurol. 29 (1991) 601-605
87. Pandolfo M. Friedreich ataxia. Arch. Neurol. 65 (2008) 1296-1303
88. Campuzano V., Montermini L., Moltò M.D., Pianese L., Cossée M., Cavalcanti F., Monros E., Rodius F., Duclos F., Monticelli A., Zara F., Cañizares J., Koutnikova H., Bidichandani S.I., Gellera C., Brice A., Trouillas P., De Michele G., Filla A., De Frutos R., Palau F., Patel P.I., Di Donato S., Mandel J.L., Cocozza S., Koenig M., and Pandolfo M. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271 (1996) 1423-1427
89. Cossée M., Dürr A., Schmitt M., Dahl N., Trouillas P., Allinson P., Kostrzewa M., Nivelon Chevallier A., Gustavson K.H., Kohlschütter A., Müller U., Mandel J.L., Brice A., Koenig M., Cavalcanti F., Tammaro A., De Michele G., Filla A., Cocozza S., Labuda M., Montermini L., Poirier J., and Pandolfo M. Friedreich's ataxia: point mutations and clinical presentation of compound Heterozygotes. Ann. Neurol. 45 (1999) 200-206
90. Rötig A., de Lonlay P., Chretien D., Foury F., Koenig M., Sidi D., Munnich A., and Rustin P. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat. Genet. 17 (1997) 215-217
91. Lodi R., Cooper J.M., Bradley J.L., Manners D., Styles P., Taylor D.J., and Schapira A.H. Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 11492-11495
92. Carroll W.M., Kriss A., Baraitser M., Barrett G., and Halliday A.M. The incidence and nature of visual pathway involvement in Friedreich's ataxia, a clinical and visual evoked potential study of 22 patients. Brain 103 (1980) 413-434
93. Givre S.J., Wall M., and Kardon R.H. Visual loss and recovery in a patient with Friedreich ataxia. J. Neuro-Ophthalmol. 20 (2000) 229-233
94. Porter N., Downes S.M., Fratter C., Anslow P., and Nemeth A.H. Catastrophic visual loss in a patient with Friedreich ataxia. Arch. Ophthalmol. 125 (2007) 273-274
95. Mohr J., and Mageroy K. Sex-linked deafness of a possibly new type. Acta Genet. Stat. Med. 10 (1960) 54-62
96. Tranebjaerg L., Schwartz C., Eriksen H., Andreasson S., Ponjavic V., Dahl A., Stevenson R.E., May M., Arena F., Barker D., et al. A new X linked recessive deafness syndrome with blindness, dystonia, fractures and mental deficiency is linked to Xq22. J. Med. Genet. 32 (1995) 257-263
97. Jin H., May M., Tranebjaerg L., Kendall E., Fontán G., Jackson J., Subramony S.H., Arena F., Lubs H., Smith S., Stevenson R., Schwartz C., and Vetrie D. A novel X-linked gene, DDP, shows mutations in families with deafness (DFN-1), dystonia, mental deficiency and blindness. Nat. Genet. 14 (1996) 177-180
98. Koehler C.M., Leuenberger D., Merchant S., Renold A., Junne T., and Schatz G. Human deafness dystonia syndrome is a mitochondrial disease. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 2141-2146
99. Neupert W., and Herrmann J.M. Translocation of proteins into mitochondria. Annu. Rev. Biochem. 76 (2007) 723-749
100. Pizzuti A., Fabbrini G., Salehi L., Vacca L., Inghilleri M., Dallapiccola B., and Berardelli A. Focal dystonia caused by Mohr-Tranebjaerg syndrome with complete deletion of the DDP1 gene. Neurology 62 (2004) 1021-1022
101. Roesch K., Curran S.P., Tranebjaerg L., and Koehler C.M. Human deafness dystonia syndrome is caused by a defect in assembly of the DDP1/TIMM8a-TIMM13 complex. Hum. Mol. Genet. 11 (2002) 477-486
102. Swerdlow R.H., and Wooten G.F. A novel deafness/dystonia peptide gene mutation that causes dystonia in female carriers of Mohr-Tranebjaerg syndrome. Ann. Neurol. 50 (2001) 537-540
103. Binder J., Hofmann S., Kreisel S., Wöhrle J.C., Bäzner H., Krauss J.K., Hennerici M.G., and Bauer M.F. Clinical and molecular findings in a patient with a novel mutation in the deafness dystonia peptide (DDP1) gene. Brain 126 (2003) 1814-1820
104. Ponjavic V., Andreasson S., Tranebjaerg L., and Lubs H.A. Full-field electroretinograms in a family with Mohr-Tranebjaerg syndrome. Acta Ophthalmol. Scand. 74 (1996) 632-635
105. Stevanin G., Ruberg M., and Brice A. Recent advances in the genetics of spastic paraplegias. Curr. Neurol. Neurosci. Rep. 8 (2008) 198-210
106. Salinas S., Proukakis C., Crosby A., and Warner T.T. Hereditary spastic paraplegia: clinical features and pathogenetic mechanisms. Lancet Neurol. 7 (2008) 1127-1138
107. Makhoul J., Cordonnier M., and Van Nechel C. Optic neuropathy in Strumpell-Lorrain disease: presentation of a clinical case and literature review. Bull. Soc. Belge. Ophtalmol. 286 (2002) 9-14
108. Hansen J.J., Dürr A., Cournu-Rebeix I., Georgopoulos C., Ang D., Nielsen M.N., Davoine C.S., Brice A., Fontaine B., Gregersen N., and Bross P. Hereditary spastic paraplegia SPG13 is associated with a mutation in the gene encoding the mitochondrial chaperonin Hsp60. Am. J. Hum. Genet. 70 (2002) 1328-1332
109. Züchner S., Wang G., Tran-Viet K.N., Nance M.A., Gaskell P.C., Vance J.M., Ashley-Koch A.E., and Pericak-Vance M.A. Mutations in the novel mitochondrial protein REEP1 cause hereditary spastic paraplegia type 31. Am. J. Hum. Genet. 79 (2006) 365-369
110. Atorino L., Silvestri L., Koppen M., Cassina L., Ballabio A., Marconi R., Langer T., and Casari G. Loss of m-AAA protease in mitochondria causes complex I deficiency and increased sensitivity to oxidative stress in hereditary spastic paraplegia. J. Cell. Biol. 163 (2003) 777-787
111. Ferreirinha F., Quattrini A., Pirozzi M., Valsecchi V., Dina G., Broccoli V., Auricchio A., Piemonte F., Tozzi G., Gaeta L., Casari G., Ballabio A., and Rugarli E.I. Axonal degeneration in paraplegin-deficient mice is associated with abnormal mitochondria and impairment of axonal transport. J. Clin. Invest. 113 (2004) 231-242
112. Rugarli E.I., and Langer T. Translating m-AAA protease function in mitochondria to hereditary spastic paraplegia. Trends Mol. Med. 12 (2006) 262-269
113. Ishihara N., Fujita Y., Oka T., and Mihara K. Regulation of mitochondrial morphology through proteolytic cleavage of OPA1. EMBO J. 25 (2006) 2966-2977
114. Duvezin-Caubet S., Koppen M., Wagener J., Zick M., Israel L., Bernacchia A., Jagasia R., Rugarli E.I., Imhof A., Neupert W., Langer T., and Reichert A.S. OPA1 processing reconstituted in yeast depends on the subunit composition of the m-AAA protease in mitochondria. Mol. Biol. Cell. 18 (2007) 3582-3590
115. Guillery O., Malka F., Landes T., Guillou E., Blackstone C., Lombès A., Belenguer P., Arnoult D., and Rojo M. Metalloprotease-mediated OPA1 processing is modulated by the mitochondrial membrane potential. Biol. Cell. 100 (2008) 315-325
116. Waterham H.R., Koster J., van Roermund C.W., Mooyer P.A., Wanders R.J., and Leonard J.V. A lethal defect of mitochondrial and peroxisomal fission. N. Engl. J. Med. 356 (2007) 1736-1741
117. Van Goethem G., Dermaut B., Lofgren A., Martin J.J., and Van Broeckhoven C. Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA Deletions. Nat. Genet. 28 (2001) 211-212
118. Longley M.J., Clark S., Yu Wai Man C., Hudson G., Durham S.E., Taylor R.W., Nightingale S., Turnbull D.M., Copeland W.C., and Chinnery P.F. Mutant POLG2 disrupts DNA polymerase gamma subunits and causes progressive external ophthalmoplegia. Am. J. Hum. Genet. 78 (2006) 1026-1034
119. Spelbrink J.N., Li F.Y., Tiranti V., Nikali K., Yuan Q.P., Tariq M., Wanrooij S., Garrido N., Comi G., Morandi L., Santoro L., Toscano A., Fabrizi G.M., Somer H., Croxen R., Beeson D., Poulton J., Suomalainen A., Jacobs H.T., Zeviani M., and Larsson C. Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria. Nat. Genet. 28 (2001) 223-231
120. Kaukonen J., Juselius J.K., Tiranti V., Kyttälä A., Zeviani M., Comi G.P., Keränen S., Peltonen L., and Suomalainen A. Role of adenine nucleotide translocator 1 in mtDNA maintenance. Science 289 (2000) 782-785
121. Nishino I., Spinazzola A., and Hirano M. Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science 283 (1999) 689-692
122. Hudson G., and Chinnery P.F. Mitochondrial DNA polymerase-gamma and human disease. Hum. Mol. Genet. 15 Spec No 2 (2006) R244-R252
123. Hirano M., Lagier-Tourenne C., Valentino M.L., Martí R., and Nishigaki Y. Thymidine phosphorylase mutations cause instability of mitochondrial DNA. Gene 354 (2005) 152-156
124. Treft R.L., Sanborn G.E., Carey J., Swartz M., Crisp D., Wester D.C., and Creel D. Dominant optic atrophy, deafness, ptosis, ophthalmoplegia, dystaxia, and myopathy. A new syndrome. Ophthalmology 91 (1984) 908-915
125. Meire F., De Laey J.J., de Bie S., van Staey M., and Matton M.T. Dominant optic nerve atrophy with progressive hearing loss and chronic progressive external ophthalmoplegia (CPEO). Ophthalmic. Paediatr. Genet. 5 (1985) 91-97
126. Payne M., Yang Z., Katz B.J., Warner J.E., Weight C.J., Zhao Y., Pearson E.D., Treft R.L., Hillman T., Kennedy R.J., Meire F.M., and Zhang K. Dominant optic atrophy, sensorineural hearing loss, ptosis, and ophthalmoplegia: a syndrome caused by a missense mutation in OPA1. Am. J. Ophthalmol. 138 (2004) 749-755
127. Zeviani M. OPA1 mutations and mitochondrial DNA damage: keeping the magic circle in shape. Brain 131 (2008) 314-317
128. Stewart J.D., Hudson G., Yu-Wai-Man P., Blakeley E.L., He L., Horvath R., Maddison P., Wright A., Griffiths P.G., Turnbull D.M., Taylor R.W., and Chinnery P.F. OPA1 in multiple mitochondrial DNA deletion disorders. Neurology 71 (2008) 1829-1831
129. Harrower T., Stewart J.D., Hudson G., Houlden H., Warner G., O'Donovan D.G., Findlay L.J., Taylor R.W., De Silva R., and Chinnery P.F. POLG1 mutations manifesting as autosomal recessive axonal Charcot-Marie-Tooth disease. Arch. Neurol. 65 (2008) 133-136
130. Loiseau D., Chevrollier A., Verny C., Guillet V., Gueguen N., Pou de Crescenzo M.A., Ferré M., Malinge M.C., Guichet A., Nicolas G., Amati-Bonneau P., Malthièry Y., Bonneau D., and Reynier P. Mitochondrial coupling defect in Charcot-Marie-Tooth type 2A disease. Ann. Neurol. 61 (2007) 315-323
131. Amiott E.A., Lott P., Soto J., Kang P.B., McCaffery J.M., DiMauro S., Abel E.D., Flanigan K.M., Lawson V.H., and Shaw J.M. Mitochondrial fusion and function in Charcot-Marie-Tooth type 2A patient fibroblasts with mitofusin 2 mutations. Exp. Neurol. 211 (2008) 115-127
132. Baloh R.H., Schmidt R.E., Pestronk A., and Milbrandt J. Altered axonal mitochondrial transport in the pathogenesis of Charcot-Marie-Tooth disease from mitofusin 2 mutations. J. Neurosci. 27 (2007) 422-430
133. Kleta R., Skovby F., Christensen E., Rosenberg T., Gahl W.A., and Anikster Y. 3-Methylglutaconic aciduria type III in a non-Iraqi-Jewish kindred: clinical and molecular findings. Mol. Genet. Metab. 76 (2002) 201-206
134. Davies V.J., Powell K.A., White K.E., Yip W., Hogan V., Hollins A.J., Davies J.R., Piechota M., Brownstein D.G., Moat S.J., Nichols P.P., Wride M.A., Boulton M.E., and Votruba M. A missense mutation in the murine Opa3 gene models human Costeff syndrome. Brain 131 (2008) 368-380
135. Birch-Machin M.A., Taylor R.W., Cochran B., Ackrell B.A., and Turnbull D.M. Late-onset optic atrophy, ataxia, and myopathy associated with a mutation of a complex II gene. Ann. Neurol. 48 (2000) 330-335
136. Bruno C., Martinuzzi A., Tang Y., Andreu A.L., Pallotti F., Bonilla E., Shanske S., Fu J., Sue C.M., Angelini C., DiMauro S., and Manfredi G. A stop-codon mutation in the human mtDNA cytochrome c oxidase I gene disrupts the functional structure of complex IV. Am. J. Hum. Genet. 65 (1999) 611-620
137. Porcelli A.M., Angelin A., Ghelli A., Mariani E., Martinuzzi A., Carelli V., Petronilli V., Bernardi P., and Rugolo M. Respiratory complex I dysfunction due to mitochondrial DNA mutations shifts the voltage threshold for opening of the permeability transition pore toward resting levels. J. Biol. Chem. 284 (2009) 2045-2052
138. Suen D.F., Norris K.L., and Youle R.J. Mitochondrial dynamics and apoptosis. Genes Dev. 22 (2008) 1577-1590
139. Yen M.Y., Chen C.S., Wang A.G., and Wei Y.H. Increase of mitochondrial DNA in blood cells of patients with Leber's hereditary optic neuropathy with 11778 mutation. Br. J. Ophthalmol. 86 (2002) 1027-1030
140. Kim J.Y., Hwang J.M., Ko H.S., Seong M.W., Park B.J., and Park S.S. Mitochondrial DNA content is decreased in autosomal dominant optic atrophy. Neurology 64 (2005) 966-972
141. Chen H., and Chan D.C. Critical dependence of neurons on mitochondrial dynamics. Curr. Opin. Cell. Biol. 18 (2006) 453-459
142. Li Z., Okamoto K., Hayashi Y., and Sheng M. The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses. Cell 119 (2004) 873-887
143. Wenz T., Diaz F., and Spiegelman B.M. C.T. Moraes. Activation of the PPAR/PGC-1alpha pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype. Cell. Metab. 8 (2008) 249-256